echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > The Lancet: Fecal microbiota transplantation has a remarkable effect on the treatment of fatal intestinal infections

    The Lancet: Fecal microbiota transplantation has a remarkable effect on the treatment of fatal intestinal infections

    • Last Update: 2022-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎WuXi AppTec content team editor


    Clostridium difficile can cause colon infections and is one of the most common causes of
    nosocomial infections and death.
    Treatment options for Clostridium difficile infection are limited, and oral antibiotics (including vancomycin and metronidazole) have a certain effect, but the recurrence rate is as high as 25%~30%.

    Therefore, there is an urgent clinical need for a non-antibiotic approach to treat and prevent Clostridium difficile infection
    .

    The Lancet Gastroenterology & Hepatology has published a randomized, double-blind, placebo-controlled trial
    of fecal microbiota transplantation for Clostridium difficile infection (early).
    The results suggest that restoration of the microbiota through fecal microbiota transplantation is expected to be an effective treatment option
    for patients with multiple relapses of Clostridium difficile.

    Credit: The Lancet Gastroenterology & Hepatology
    The trial was conducted at Aarhus University Hospital in Denmark.
    Participants were 86 patients
    over the age of 18 with first or second Clostridium difficile infection.
    Patients were randomized 1:1 to fecal microbiota transplantation and placebo
    .
    All patients were first given oral vancomycin 125 mg four times daily for at least 10 days; Fecal microbiota transplantation and placebo were subsequently received in groups, with the first dose given on day 1 and the second dose given
    between days 3 and 7.

    The primary endpoint of the trial was resolution
    of Clostridium difficile-associated diarrhea (CDAD) eight weeks after treatment.
    All patients were tested
    for salmonella, Campylobacter, Yersinia, Shigella, and enteropathogenic E.
    coli using PCR.

    Because the efficacy (CDAD resolution rate) of the placebo group was significantly lower than that of the fecal microbiota transplant group (p<0.
    001) at the time of the interim analysis, the research team discontinued the trial
    for ethical reasons.
    At 8 weeks after treatment, 19 (90%) of 21 patients in the fecal microbiota transplantation group and 7 (33%) of 21 patients in the placebo group achieved resolution
    of CDAD.

    ▲ Primary and secondary trial endpoints (Image source: Reference [1]) In terms of safety, the overall incidence of adverse events in the fecal microbiota transplantation group was 95% (20/21) and 100% (21/21)
    in the placebo group.
    Among them, diarrhea and abdominal pain are the most common adverse effects
    .
    There were three serious adverse events that could be associated with study treatment (1 in the fecal microbiome transplant group; 2 in the placebo group), but there were no deaths or colectomies
    at 8 weeks follow-up.

    The trial still has some limitations
    .
    First, premature discontinuation and low patient numbers limit extrapolated analyses
    of mortality, time of onset of effect, and cost.
    In addition, the results should be considered as an additive effect of fecal microbiota transplantation after vancomycin treatment, rather than evidence of the effect of fecal microbiota transplantation alone, and initial treatment with vancomycin may prevent clinical deterioration or relapse
    before fecal microbiota transplantation.

    Overall, in this randomized, double-blind, placebo-controlled clinical trial, fecal microbiota transplantation after vancomycin treatment was superior to vancomycin alone
    in patients with first or second Clostridium difficile infection.
    The effect of fecal microbiota transplantation on microbiota recovery also reflects its potential to
    effectively manage the symptoms of early Clostridium difficile infection.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.